Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.54 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209756 | 1.00 | RAB9A (0.54) | RAB9ANPC1PLA2G7MLLT1SMYD3 | |
| SCHEMBL3600227 | 0.87 | PARP1 (0.49) | RAB9APLA2G7SMYD3 | |
| SCHEMBL3600224 | 0.87 | PARP1 (0.49) | RAB9APLA2G7SMYD3 | |
| SCHEMBL15506795 | 0.84 | TAS1R3 (0.57) | SMN1; SMN2 | |
| SCHEMBL3605671 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3 | |
| SCHEMBL3605675 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3 | |
| SCHEMBL3611578 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3 | |
| SCHEMBL17205073 | 0.83 | TAS1R3 (0.59) | RAB9ANPC1PLA2G7MLLT1SMYD3 | |
| SCHEMBL17206336 | 0.83 | TAS1R3 (0.59) | RAB9ANPC1PLA2G7MLLT1SMYD3 | |
| SCHEMBL15506757 | 0.83 | TAS1R3 (0.59) | RAB9ANPC1PLA2G7MLLT1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | UNIV JOHNS HOPKINS (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | UNIV JOHNS HOPKINS (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2016171743-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2015164482-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044100-A1 | INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | IDO2, IDO1, INMT | RAB9A 3348/4885NPC1 2930/4885PLA2G7 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.